GlassScriptPhysician profile
Tarek Aly
NPI 1225419559
$83,080.67
in general payments reported to CMS, 2019-2025
22 companies · $9,796 in 2025
The $9,796 reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $62.54 · 2021: $18K · 2022: $9,328 · 2023: $27K · 2024: $20K · 2025: $9,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Travel and Lodging: $4,448 · Food and Beverage: $2,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,050.00 |
| Travel and Lodging | $4,448.07 |
| Food and Beverage | $2,533.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $65,791.48 | 2021-2025 | Vraylar |
| Neos Therapeutics, LP | $11,509.95 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Aytu Biopharma, INC. | $3,702.85 | 2021 | |
| Corium, LLC | $389.49 | 2021-2025 | Azstarys |
| Alkermes, INC. | $317.01 | 2020-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $204.54 | 2021-2024 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $204.33 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.51 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $147.74 | 2022-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $141.57 | 2020-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $113.39 | 2022-2024 | Spravato |
| Ironshore Pharmaceuticals INC. | $88.04 | 2020-2024 | Jornay Pm |
| Almatica Pharma LLC | $61.22 | 2024 | Loreev Xr |
| Bausch Health US, LLC | $37.53 | 2024-2025 | Wellbutrin, Aplenzin |
| Noven Therapeutics, LLC | $37.31 | 2024 | Xelstrym, Secuado |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $33.49 | 2023-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $21.55 | 2025 | Cobenfy |
| Biogen, INC. | $19.31 | 2025 | Zurzuvae |
| Bioxcel Therapeutics, INC. | $17.35 | 2023 | Igalmi |
| Collegium Pharmaceutical, INC. | $16.65 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $15.62 | 2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $14.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarek Aly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.